RxERP

Serialized enterprise resource planning platform for pharmaceutical supply-chain operators.

Website: https://rxerp.com/

Cover Block

Publicly reported

Field Value
Name RxERP
Tagline Serialized enterprise resource planning platform for pharmaceutical supply-chain operators.
Headquarters Utah, US [rxerp.com]
Founded 2024 [PitchBook]
Stage Seed [Structured Facts]
Business model SaaS [Structured Facts]
Industry Logistics / Supply Chain [Structured Facts]
Technology Software (Non-AI) [Structured Facts]
Geography North America [Structured Facts]
Growth profile Venture Scale [Structured Facts]
Founding team Solo Founder [Structured Facts]
Funding label Undisclosed [Crunchbase, retrieved 2026]
Total disclosed ~$3,000,000 [PitchBook]

Links

Publicly reported

Summary and Signal

PUBLIC RxERP is a Utah-based software company building a serialized ERP for pharmaceutical supply-chain operators, and it merits attention because it is trying to collapse compliance, inventory, and operational workflows into one system at a moment when drug traceability and product-data requirements are getting tighter [RxERP] [Business Wire, November 2026]. Founded in 2024, the company presents itself as a purpose-built platform for wholesalers, distributors, manufacturers, 3PLs, and pharmacies moving into distribution, with DSCSA serialization and EPCIS traceability embedded in the system rather than attached as a separate module [RxERP]. That product positioning is the central bet: if serialization truly sits inside the core data model, RxERP could reduce reconciliation work and data inconsistency across trading partners, although that differentiation is still described primarily through company materials rather than independent technical validation [RxERP].

The public record on the founding story is still thin. Steve Madsen is identified as founder and CEO, and company materials say the product was built by operators with prior pharmaceutical distribution experience, but the independently verifiable detail on that background remains limited in the sources reviewed [RxERP] [LinkedIn]. On funding, PitchBook reports roughly $3 million raised, while Crunchbase shows an undisclosed financing entry without round detail or investor attribution, which leaves capitalization and sponsor quality only partially visible from public data [PitchBook] [Crunchbase]. The business model appears straightforward SaaS, and the company also describes itself as revenue-generating and venture-backed in public-facing materials, though those operating claims should be treated as company-reported until corroborated elsewhere [RxERP].

Over the next 12 to 18 months, the points to watch are whether RxERP can convert compliance-driven demand into repeatable enterprise deployments, whether named customer wins turn into documented production scale, and whether integrations such as its reported work with Wellgistics Health and p-Chip translate into product depth rather than one-off announcements [Wellgistics Health, Inc.] [ERP Today, February 2026]. Recent visibility around 12-digit NDC readiness and healthcare award coverage helps establish category presence, but the sharper investor question is whether the company can prove that a serialization-native ERP is a durable system of record rather than a narrow compliance layer [Bay to Bay News, November 2026] [Business Wire, November 2026].

No independent source found -- This section relies materially on company statements, with partial corroboration from PitchBook, Crunchbase, LinkedIn, and named-publisher coverage.

Taxonomy Snapshot

Axis Value
Stage Seed
Business Model SaaS
Industry / Vertical Logistics / Supply Chain
Technology Type Software (Non-AI)
Geography North America
Growth Profile Venture Scale
Founding Team Solo Founder
Funding Undisclosed (total disclosed ~$3,000,000)

Company Overview

PUBLIC

RxERP presents as a narrowly focused software company rather than a broad healthcare IT vendor. The company says it is building a serialized ERP platform for pharmaceutical supply-chain operators, with DSCSA workflows and traceability embedded into the operating system used by distributors, manufacturers, and adjacent trading partners [rxerp.com]. Crunchbase lists the company as founded in 2024 and based in Utah, which aligns with the company site’s positioning around pharmaceutical compliance and supply-chain operations [Crunchbase] [rxerp.com].

The public record is still thin on formal corporate detail, but the operating profile is reasonably clear. Crunchbase identifies Steve Madsen as founder, while the company site frames RxERP around a single core product category, serialized pharmaceutical ERP software, rather than a multi-product suite [Crunchbase] [rxerp.com]. That matters because the early company narrative appears to be organized around one claim: serialization is not an add-on module, but the base data model of the system itself, according to the company website [rxerp.com].

Chronology is limited but usable. The company was founded in 2024, according to Crunchbase, and by 2026 its website was publishing product and regulatory content tied to DSCSA operations and 12-digit NDC readiness, suggesting a go-to-market motion centered on compliance-driven workflows in U.S. pharma distribution [Crunchbase] [rxerp.com]. Crunchbase also shows an undisclosed funding event and attributes roughly $3 million in funding to the company profile, though round date, lead investor, and valuation are not established in the sources permitted for this section [Crunchbase].

One source, partially checked -- Confirmed primarily by Crunchbase and the company website; core facts align across both, but legal entity detail and milestone depth remain limited in the permitted source set.

The Product and the Stack

Public record plus analysis

What stands out first is not a novel model layer or a single workflow tool, but an attempt to collapse compliance, inventory, and back-office operations into one serialized system for pharmaceutical operators. RxERP describes its product as "the only fully serialized ERP built for the pharmaceutical supply chain" and says the platform combines inventory, DSCSA compliance, e-commerce and ordering, CRM, invoicing, reporting, warehouse operations, financial management, and EPCIS traceability in one application [RxERP]. The core product claim is architectural: serialization is embedded in the ERP data model itself, rather than handled through a separate serialization system that can create data mismatches across trading partners, according to the company website [RxERP].

The buyer framing is similarly specific. Public materials position the software for wholesalers, distributors, micro-distributors, 3PL providers, manufacturers, government users, and pharmacies expanding into distribution, which suggests RxERP is targeting operational complexity at the point where DSCSA traceability requirements start to interfere with day-to-day fulfillment and finance workflows [RxERP]. That is a credible wedge if the product performs as advertised, though the evidence in public view is still mostly company-authored and does not include a verified product demo, independent implementation metrics, or detailed technical documentation [RxERP].

There are also a few externally surfaced signals that the product surface is broadening around adjacent compliance and payment workflows. RxERP says it offers cash application automation on its website [RxERP]. Separately, ERP Today reported in February 2026 that the company entered a licensing agreement with p-Chip Corporation to integrate microtransponder technology for pharmaceutical traceability, and Wellgistics Health said RxERP was integrated into a payment flow supporting XRP, ACH, and credit card payments for pharmacy customers [ERP Today, February 2026] [Wellgistics Health, Inc.]. Those announcements point to an effort to extend beyond recordkeeping into traceability infrastructure and transaction processing, but they should still be read as early commercial signals rather than proof of scaled deployment.

No independent source found -- This section relies primarily on company website product descriptions, with limited third-party corroboration from ERP Today and Wellgistics Health.

The Market They Are Entering

PUBLIC

The market matters now because pharmaceutical supply-chain software is being pulled by regulation rather than by discretionary IT budgets, and RxERP is positioned around that compliance trigger rather than around generalized ERP replacement [RxERP, retrieved 2026] [Business Wire, November 2026].

Public evidence does not support a clean TAM, SAM, or SOM build for RxERP itself. No named third-party market report was provided for serialized pharmaceutical ERP, so the more defensible approach is to frame the addressable demand through adjacent, publicly evidenced markets: pharmaceutical traceability and DSCSA compliance workflows, wholesale and specialty distribution software, and ERP systems adapted for regulated inventory environments [RxERP, retrieved 2026] [Business Wire, November 2026]. That matters because the company is not selling a generic back-office stack. It is selling a system of record for operators that need inventory, transaction data, compliance reporting, and trading-partner workflows to reconcile inside one platform [RxERP, retrieved 2026].

The demand signal in the source set is mostly regulatory and operational. RxERP's own positioning centers on DSCSA serialization, EPCIS traceability, and audit readiness, while its November 2026 commentary on the FDA's move toward 12-digit NDCs suggests another layer of product-data normalization work for manufacturers and distributors [RxERP, retrieved 2026] [Business Wire, November 2026] [Bay to Bay News, November 2026]. In practical terms, that creates budget room for software that reduces exception handling and duplicate product records across trading partners, especially for wholesalers, micro-distributors, 3PLs, and pharmacies moving into distribution workflows [RxERP, retrieved 2026].

The adjacent and substitute markets are broader than serialized ERP alone. Buyers could address the same problem set through stand-alone serialization and traceability tools, warehouse and distribution software, compliance reporting systems, or incumbent ERP deployments with pharma-specific extensions [RxERP, retrieved 2026]. That widens the competitive field, but it also clarifies the thesis behind RxERP's product design: if compliance remains a bolt-on, customers may still face mismatched data across inventory, ordering, invoicing, and traceability records, which is the integration problem the company claims to solve at the data-model level [RxERP, retrieved 2026].

The macro and regulatory backdrop is the strongest external tailwind visible in public sources. DSCSA requirements already shape how pharmaceutical product movement is documented, and the discussion around 12-digit NDC formatting points to a second-order systems issue, not just a labeling change [Business Wire, November 2026] [Bay to Bay News, November 2026]. For a younger vendor, that kind of rule-driven demand can accelerate evaluation cycles, although public materials here do not establish how large that conversion opportunity is or how much of it sits with greenfield buyers versus replacement projects.

Market lens Public evidence Relevance to RxERP
Serialized pharmaceutical ERP Company positions itself as a serialized ERP for the pharmaceutical supply chain [RxERP, retrieved 2026] Core category definition, but not independently sized
DSCSA compliance and EPCIS traceability Product and messaging emphasize DSCSA workflows and EPCIS traceability [RxERP, retrieved 2026] Primary regulatory buying trigger
12-digit NDC readiness Company published guidance on FDA's move to 12-digit NDCs [Business Wire, November 2026] [Bay to Bay News, November 2026] Expands the data-management and migration burden for pharma operators
Pharma distribution software Target users include wholesalers, distributors, micro-distributors, 3PLs, manufacturers, and pharmacies expanding into distribution [RxERP, retrieved 2026] Defines the practical buyer set more clearly than ERP alone

The table shows a market that is easier to describe through pain points than through a verified headline market size. That is not unusual for narrow infrastructure categories, but it means the investment case depends less on abstract software TAM and more on whether regulation continues to force system upgrades in exactly the customer segments RxERP targets.

No independent source found -- This section relies primarily on company materials, with partial corroboration from Business Wire and Bay to Bay News for the 12-digit NDC and awards-related context, but no independent third-party market sizing was provided.

The Competitive Field

Competitive map

MIXED RxERP is positioning itself against established pharma compliance and traceability software by arguing that serialization should sit inside the ERP itself, rather than beside it as a separate system [RxERP, retrieved 2026].

Company Positioning Stage / Funding Notable Differentiator Source
RxERP Serialized ERP for pharmaceutical supply-chain operators Seed; disclosed funding reported at about $3 million Claims serialization is native to the ERP data model, spanning inventory, DSCSA compliance, ordering, CRM, invoicing, reporting, warehouse operations, financial management, and EPCIS traceability [RxERP, retrieved 2026]; [PitchBook, retrieved 2026]
TraceLink DSCSA compliance, serialization, and digital supply network software for life sciences Funding not established in the provided research Named competitor in the structured facts; category overlap is clearest around serialization and traceability workflows [Structured Facts]

The practical map is narrower than the broad pharmaceutical software label suggests. RxERP's public materials point to buyers such as wholesalers, distributors, micro-distributors, 3PL providers, manufacturers, and pharmacies expanding into distribution, which places it at the intersection of ERP, compliance infrastructure, and distribution operations software [RxERP, retrieved 2026]. In that frame, incumbents are the established compliance and traceability vendors already embedded in DSCSA workflows, while adjacent substitutes include general ERP systems paired with bolt-on serialization tools.

RxERP's edge today appears to be product architecture and regulatory specificity, though both are still mostly documented through company materials. The company says serialization is built into the core ERP data model rather than managed through a separate serialization layer, and that should matter if customers are struggling with duplicate records, reconciliation work, and audit complexity across trading partners [RxERP, retrieved 2026]. That edge is potentially durable if data structure and workflow depth create switching costs once a distributor is live, but it is also perishable because larger compliance vendors can respond at the integration layer, and the public record here does not yet show independently reported deployment scale, ecosystem lock-in, or channel ownership [RxERP, retrieved 2026]; [PitchBook, retrieved 2026].

The company's exposure is easiest to see where enterprise trust and network reach matter more than architecture purity. RxERP also looks more exposed in segments where a buyer wants a broad enterprise platform with long procurement history, or where partnerships and systems integrators drive vendor selection. The available public evidence does show customer announcements and product updates, including work around 12-digit NDC readiness and a p-Chip licensing agreement, but it does not yet establish that RxERP owns a distribution channel that competitors cannot access [Bay to Bay News, November 2026]; [ERP Today, February 2026].

The most plausible 18-month scenario is a split market rather than a winner-take-all outcome. Winner if compliance-driven distributors keep prioritizing a single system of record for inventory, serialization, and finance: RxERP, because its pitch is strongest where DSCSA complexity is forcing operational redesign rather than incremental tooling [RxERP, retrieved 2026].

Opportunity

PUBLIC The prize here is not a generic ERP outcome, it is the chance to become the system of record for regulated pharmaceutical product movement at the point where compliance, inventory, and financial workflows collide.

The headline opportunity is straightforward. If RxERP can turn its serialization-native architecture into the default operating stack for small and mid-market pharmaceutical distributors, wholesalers, micro-distributors, 3PLs, and pharmacies moving into distribution, it could occupy a category that larger horizontal ERP vendors and stand-alone compliance tools have historically split between them [RxERP, retrieved 2026]. That outcome is still early, but it is not purely aspirational on the evidence available: the company was founded in 2024, is described as revenue-generating and venture-backed in company materials, has a disclosed funding figure of roughly $3 million in PitchBook, and publicly presents named customer references including Cedra Healthcare and Independent Pharmaceutical alongside a wider customer list on its site [PitchBook, retrieved 2026] [RxERP, retrieved 2026] [Finance Yahoo, October 2026] [Business Wire, May 2026]. The core claim that matters is not the marketing superlative, but the product design choice underneath it: serialization and EPCIS traceability are presented as part of the ERP data model rather than as a bolt-on workflow, which is a sensible wedge in a market shaped by DSCSA compliance and product identity complexity [RxERP, retrieved 2026].

A plausible path to scale depends less on broad software ambition and more on a narrow operational truth. In pharmaceutical distribution, a system that handles product identity, traceability, ordering, invoicing, and cash workflows in one place can become unusually sticky because replacement risk rises with every regulated process moved onto the platform [RxERP, retrieved 2026]. Recent public activity, including content around 12-digit NDC readiness, a customer transition announcement with Independent Pharmaceutical, and an embedded traceability licensing agreement with p-Chip, suggests the company is trying to widen that wedge from compliance into day-to-day operations [Bay to Bay News, November 2026] [Business Wire, May 2026] [ERP Today, February 2026].

Scenario What happens Catalyst Why its plausible
Compliance system of record RxERP becomes the default platform for smaller pharmaceutical distributors and wholesalers that need ERP and DSCSA traceability in one stack Continued regulatory complexity around DSCSA workflows and adjacent product-data changes such as 12-digit NDC readiness The product is explicitly positioned around serialized ERP, audit readiness, EPCIS traceability, and product-data normalization, all of which map to recurring compliance pain points [RxERP, retrieved 2026] [Business Wire, November 2026] [Bay to Bay News, November 2026]
Expansion through adjacent payment and operations rails RxERP grows from core ERP into payment, AR, and cash application workflows that make it harder to displace More integrations like the Wellgistics Health payment connection, plus adoption by pharmacies expanding into distribution The company already markets financial automation and cash application capabilities, and a public integration ties the platform to payment options including ACH and card rails [RxERP, retrieved 2026] [Wellgistics Health, Inc., retrieved 2026]
Traceability infrastructure beyond software RxERP uses traceability tooling and partner technologies to become part of the physical-to-digital chain of custody stack Commercial uptake of the p-Chip licensing agreement in regulated traceability use cases The p-Chip agreement shows willingness to extend beyond pure workflow software into deeper traceability infrastructure, which could raise switching costs if adopted in customer operations [ERP Today, February 2026]

The compounding mechanism, if it appears, would come from workflow density rather than consumer-style network effects. A customer that starts with compliance has reason to add inventory, ordering, CRM, invoicing, reporting, warehouse operations, and financial management if those modules share the same serialized product record, because every added function reduces reconciliation work and exception handling across trading partners [RxERP, retrieved 2026]. That in turn can improve retention, create more implementation references in a tightly regulated niche, and make adjacent integrations more valuable. Public customer announcements from Cedra Healthcare and Independent Pharmaceutical matter less for their logo value than for what they imply operationally: the company is selling into real distribution transitions, not only publishing thought leadership around regulation [Finance Yahoo, October 2026] [Business Wire, May 2026].

The size of the win is still best framed conditionally because no confirmed market-sizing dataset or valuation benchmark is in the record provided here. On the public evidence alone, the upside case is that a compliance-native ERP for pharmaceutical supply-chain operators becomes a strategic asset class, either as an independent vertical software company or as an acquisition target for a larger ERP, supply-chain, or healthcare IT platform seeking DSCSA-native infrastructure. If the strongest scenario above plays out, the company could support a venture-scale outcome measured in the high hundreds of millions of dollars in enterprise value (scenario, not a forecast), but the public record here is not strong enough to narrow that range responsibly without importing external comparables not in evidence.

One source, partially checked -- This section relies on company materials, named-publisher coverage, and PitchBook for partial corroboration, but several core product and customer-positioning claims remain company-sourced.

Sources

Publicly reported

  1. [rxerp.com, retrieved 2026] Serialized Pharmaceutical ERP Software Built for the Pharma Supply Chain | https://rxerp.com/

  2. [PitchBook, retrieved 2026] RxERP 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/597287-71

  3. [Crunchbase, retrieved 2026] RxERP | Financial Details | https://www.crunchbase.com/organization/rxerp/company_financials

  4. [Business Wire, November 2026] RxERP Outlines What the FDA’s Move to 12-Digit NDCs Means for Pharma Product Data | https://www.businesswire.com/news/home/20261120397394/en/RxERP-Outlines-What-the-FDAs-Move-to-12-Digit-NDCs-Means-for-Pharma-Product-Data

  5. [LinkedIn, retrieved 2026] Rich Rasmussen | RxERP | LinkedIn | https://www.linkedin.com/in/rich-rasmussen/

  6. [Wellgistics Health, Inc., retrieved 2026] Wellgistics Health, Inc. | https://wellgisticshealth.com/

  7. [ERP Today, February 2026] RxERP integrated embedded microtransponder technology for improved pharmaceutical traceability through a licensing agreement with p-Chip Corporation | https://erp.today/rxerp-integrates-p-chip-microtransponder-technology/

  8. [Bay to Bay News, November 2026] RxERP Wins Gold in Two Categories at the 2026 Merit Awards for Healthcare | https://baytobaynews.com/cambridge/stories/rxerp-wins-gold-in-two-categories-at-the-2026-merit-awards-for-healthcare,360669

  9. [Structured Facts, retrieved 2026] Structured facts provided for this report | https://startuply.local/structured-facts

  10. [Finance Yahoo, October 2026] Cedra Healthcare Selects RxERP to Support Compliant Expansion into Pharmaceutical Distribution | https://finance.yahoo.com/healthcare/articles/cedra-healthcare-selects-rxerp-support-140700292.html

  11. [Business Wire, May 2026] Independent Pharmaceutical Partners with RxERP to Complete Full ERP Transition Through New Hub Platform | https://www.businesswire.com/news/home/20260526053930/en/Independent-Pharmaceutical-Partners-with-RxERP-to-Complete-Full-ERP-Transition-Through-New-Hub-Platform

Articles about RxERP

View on Startuply.vc